GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » YoY EPS Growth

Kadmon Holdings (Kadmon Holdings) YoY EPS Growth : -33.33% (As of Sep. 2021)


View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Kadmon Holdings's YoY EPS Growth for the quarter that ended in Sep. 2021 was -33.33%.

Kadmon Holdings's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $-0.20.


Kadmon Holdings YoY EPS Growth Historical Data

The historical data trend for Kadmon Holdings's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings YoY EPS Growth Chart

Kadmon Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
YoY EPS Growth
Get a 7-Day Free Trial -143.56 85.42 59.15 17.24 -39.58

Kadmon Holdings Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.39 -88.89 10.53 -5.88 -33.33

Kadmon Holdings YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Kadmon Holdings's YoY EPS Growth for the fiscal year that ended in Dec. 2020 is calculated as:

YoY EPS Growth (A: Dec. 2020 )
=(Earnings per Share (Diluted) (A: Dec. 2020 )-Earnings per Share (Diluted) (A: Dec. 2019 ))/ | Earnings per Share (Diluted) (A: Dec. 2019 ) |
=(-0.67--0.48)/ | -0.48 |
=-39.58 %

Kadmon Holdings's YoY EPS Growth for the quarter that ended in Sep. 2021 is calculated as:

YoY EPS Growth (Q: Sep. 2021 )
=(Earnings per Share (Diluted) (Q: Sep. 2021 )-Earnings per Share (Diluted) (Q: Sep. 2020 )) / | Earnings per Share (Diluted) (Q: Sep. 2020 )) |
=(-0.2--0.15)/ | -0.15 |
=-33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadmon Holdings YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadmon Holdings (Kadmon Holdings) Business Description

Traded in Other Exchanges
N/A
Address
450 East 29th Street, New York, NY, USA, 10016
Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.
Executives
Harlan Waksal director, officer: President, CEO WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer director C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris director 103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan officer: Executive Vice President, CMO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan officer: EVP, Chief Financial Officer 450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver officer: Principal Accounting Officer, Controller 450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss officer: EVP, General Counsel, Chief Compliance Officer 450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc other: Former 10% owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon officer: Exec VP, GC, Chief Admin, Comp C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016

Kadmon Holdings (Kadmon Holdings) Headlines

From GuruFocus